首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1547784

全球靜脈免疫球蛋白市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Intravenous Immunoglobulin Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 128 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球靜脈免疫球蛋白市場需求預計將從2023年的133億美元達到2032年近270億美元的市場規模，2024-2032年研究期間複合年成長率為8.19%。

靜脈注射免疫球蛋白（IVIG）是一種有助於治療抗體缺乏症患者的療法。它是由數千名健康人血漿中的免疫球蛋白（抗體）製成的血液製品，用於對抗感染。免疫球蛋白是由漿細胞產生的醣蛋白。由於 IVIG 是由血漿製備的，因此高度純化，因此發生血液傳染的機會極低。這種療法有助於治療多種疾病，如川崎病、紅斑性狼瘡、格林巴利症候群、肌肉炎、慢性發炎性脫髓鞘性多發性神經病變（CIDP）以及免疫缺陷如免疫性血小板減少症。除此之外，它也用於治療一些神經系統疾病，例如多發性硬化症或重症肌無力。

市場動態

全球靜脈注射免疫球蛋白市場主要受到老年人口成長、免疫缺陷疾病高盛行率、血友病患者數量不斷增加、IVIG治療接受度增加以及靜脈注射免疫球蛋白藥物計畫投資增加的推動。免疫缺陷症患者數量的增加是增加靜脈免疫球蛋白治療需求的主要因素。根據美國國家過敏和傳染病研究所 (NIAID) 的數據，有超過 200 種不同形式的原發性免疫缺陷疾病 (PIDD)，在美國約有 50 萬人患有此類 PIDD。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球靜脈免疫球蛋白市場的每個細分市場進行了包容性評估。靜脈免疫球蛋白產業的成長和趨勢為本研究提供了整體方法。

市場區隔

靜脈免疫球蛋白市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人口統計數據以及即將到來的機會。

按申請

低丙種球蛋白血症
CIPD
免疫缺乏疾病
先天性愛滋病
慢性淋巴球白血病
重症肌無力
多灶性運動神經病變
ITP
川崎病
格林巴利症候群
其他

按配銷通路

醫院藥房
專業藥房
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲靜脈免疫球蛋白市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。靜脈注射免疫球蛋白市場的主要參與者包括 Biotest AG、Baxter International Inc.、Octapharma AG、LFB Biotechnologies、Grifols SA、CSL Behring、China Biologics Products Inc.、Kedrion Biopharma、BDI Pharma Inc.。種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：靜脈免疫球蛋白公司的競爭格局

靜脈免疫球蛋白市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Biotest AG

公司概況
公司收入
產品
最新動態

Baxter International Inc.

公司概況
公司收入
產品
最新動態

Octapharma AG

公司概況
公司收入
產品
最新動態

LFB Biotechnologies

公司概況
公司收入
產品
最新動態

Grifols SA

公司概況
公司收入
產品
最新動態

CSL Behring

公司概況
公司收入
產品
最新動態

China Biologics Products Inc.

公司概況
公司收入
產品
最新動態

Kedrion Biopharma

公司概況
公司收入
產品
最新動態

BDI Pharma Inc

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11213403

The global demand for Intravenous Immunoglobulin Market is presumed to reach the market size of nearly USD 27 Billion by 2032 from USD 13.3 Billion in 2023 with a CAGR of 8.19% under the study period 2024-2032.

Intravenous Immunoglobulin (IVIG) refers to a therapy that helps in treating patients with antibody deficiencies. It is a blood product made by immunoglobulin's (antibodies) from the plasma of thousands of healthy people to fight infections. Immunoglobulin's are glycoprotein's which are produced from the plasma cells. As IVIG is prepared from plasma, it is highly purified so the chances of developing a blood-borne infection are exceptionally low. This therapy helps in treating a large number of diseases such as kawasaki disease, lupus, guillain-barre syndrome, myositis, chronic inflammatory demyelinating polyneuropathy (CIDP) and also immune deficiencies such as immune thrombocytopenia. In addition to this it is also used for treating some neurological diseases such as multiple sclerosis or myasthenia gravis.

MARKET DYNAMICS

The global Intravenous Immunoglobulin Market is majorly driven by growing elderly population, high prevalence of immunodeficiency diseases, growing number of hemophilic patients, increase in acceptance of IVIG treatments and rising investment in intravenous immunoglobulin medication projects. Increasing number of patients with immunodeficiency disorders is the major factor boosting the demand of Intravenous Immunoglobulin therapy. As per National Institute of Allergy and Infectious diseases (NIAID) there are over 200 different forms of primary immune deficiency diseases (PIDDs) and around 500,000 people in the United States suffering from such PIDDS.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Intravenous Immunoglobulin. The growth and trends of Intravenous Immunoglobulin industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Intravenous Immunoglobulin market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

Hypogammaglobulinemia
CIPD
Immunodeficiency Diseases
Congenital AIDS
Chronic Lymphocytic Leukemia
Myasthenia Gravis
Multifocal Motor Neuropathy
ITP
Kawasaki Disease
Guillain-barre Syndrome
Others

By Distribution Channel

Hospital Pharmacy
Specialty Pharmacy
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Intravenous Immunoglobulin market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Intravenous Immunoglobulin market include Biotest AG, Baxter International Inc., Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma, BDI Pharma Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. INTRAVENOUS IMMUNOGLOBULIN - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By Distribution Channel
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS BY APPLICATION

5.1. Overview By Application
5.2. Historical and Forecast Data
5.3. Analysis By Application
5.4. Hypogammaglobulinemia Historic and Forecast Sales By Regions
5.5. CIPD Historic and Forecast Sales By Regions
5.6. Immunodeficiency Diseases Historic and Forecast Sales By Regions
5.7. Congenital AIDS Historic and Forecast Sales By Regions
5.8. Chronic Lymphocytic Leukemia Historic and Forecast Sales By Regions
5.9. Myasthenia Gravis Historic and Forecast Sales By Regions
5.10. Multifocal Motor Neuropathy Historic and Forecast Sales By Regions
5.11. ITP Historic and Forecast Sales By Regions
5.12. Kawasaki Disease Historic and Forecast Sales By Regions
5.13. Guillain-barre Syndrome Historic and Forecast Sales By Regions
5.14. Others Historic and Forecast Sales By Regions

6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL

6.1. Overview By Distribution Channel
6.2. Historical and Forecast Data
6.3. Analysis By Distribution Channel
6.4. Hospital Pharmacy Historic and Forecast Sales By Regions
6.5. Specialty Pharmacy Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE INTRAVENOUS IMMUNOGLOBULIN COMPANIES

8.1. Intravenous Immunoglobulin Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF INTRAVENOUS IMMUNOGLOBULIN INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Biotest AG
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Baxter International Inc.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Octapharma AG
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. LFB Biotechnologies
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Grifols SA
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. CSL Behring
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. China Biologics Products Inc.
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Kedrion Biopharma
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. BDI Pharma Inc
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments